Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial
作者： Meredith M Regan , Opeyemi A Jegede , Charlene M Mantia , Thomas Powles , Lillian Werner
DOI:
关键词:
摘要: Purpose: Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity may persist. We …
aacrjournals.org参考文章(0)